KRAS and colorectal cancer: IMO is a novel second-generation, modified, immunomodulatory TLR9 agonist and was proven to synergistically inhibit tumour growth by improving the ADCC activity of cetuximab in a cetuximab-resistant colorectal cancer line and a mouse model regardless of KRAS genotype [55, 56].